BIOGEN AMENDS SANGAMO STAKE: Ownership Change as of Dec 31, 2023
Ticker: SGMO · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | SC 13G/A |
| Filed Date | Feb 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: institutional-ownership, amendment, biotech, stake-change
TL;DR
**Biogen changed its stake in Sangamo, signaling a potential shift in their investment.**
AI Summary
Biogen Inc. filed an amended Schedule 13G/A on February 12, 2024, indicating a change in its ownership of Sangamo Therapeutics, Inc. common stock as of December 31, 2023. This filing, an amendment to a previous disclosure, signals that Biogen's stake in Sangamo has likely decreased or changed in a way that alters prior disclosures, which could impact investor perception of Sangamo's future prospects given Biogen's role as a significant partner.
Why It Matters
This filing shows a change in a major institutional investor's position, which can influence market sentiment and potentially signal future strategic shifts for Sangamo Therapeutics.
Risk Assessment
Risk Level: medium — A change in a significant institutional holding can introduce uncertainty about future collaboration or investment, posing a moderate risk to Sangamo's stock price.
Analyst Insight
Investors should monitor Sangamo's stock performance and look for further disclosures from Biogen or Sangamo regarding their partnership or Biogen's investment strategy, as a significant change in institutional ownership can impact investor confidence.
Key Players & Entities
- Biogen Inc. (company) — the reporting person filing the SC 13G/A
- Sangamo Therapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- February 12, 2024 (date) — the filing date of the SC 13G/A
- 005-59049 (number) — SEC file number for Sangamo Therapeutics, Inc.
Forward-Looking Statements
- Biogen's reduced stake could lead to a short-term dip in Sangamo's stock price. (Sangamo Therapeutics, Inc.) — medium confidence, target: Q1 2024
FAQ
What type of filing is this document and what does it signify?
This document is an SC 13G/A, which is an amendment to a Schedule 13G. It signifies a change in beneficial ownership of 5% or more of a company's stock by an institutional investor, in this case, Biogen Inc. regarding Sangamo Therapeutics, Inc.
Who is the reporting person in this filing?
The reporting person is BIOGEN INC., with a Central Index Key (CIK) of 0000875045, located at 225 BINNEY STREET, CAMBRIDGE, MA.
Who is the subject company whose securities are being reported?
The subject company is SANGAMO THERAPEUTICS, INC., with a Central Index Key (CIK) of 0001001233, located at 501 CANAL BLVD., RICHMOND, CA.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 31, 2023, as stated in the filing.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock, $0.01 par value, of Sangamo Therapeutics, Inc. is 800677106, as indicated on the cover page of the filing.
Filing Stats: 679 words · 3 min read · ~2 pages · Grade level 7.5 · Accepted 2024-02-12 19:11:00
Key Financial Figures
- $0.01 — INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti
Filing Documents
- d662582dsc13ga.htm (SC 13G/A) — 38KB
- 0001193125-24-032402.txt ( ) — 40KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this BIOGEN INC. By: /s/ Michael Dambach Name: Michael Dambach Title: Treasurer BIOGEN MA INC. By: /s/ Michael Dambach Michael Dambach Treasurer Date: February 12, 2024